OX40/OX40L blockade in vivo is generally effective in many models with autoimmune diseases, mainly by inhibiting activation and migration of CD4+ T cells and altering cytokine production (34, 118, 119) (Table 3). The gene discussed is TNFRSF4; the disease is autoimmune disease.